Biome Australia (BIO) investor relations material

Executive summary

• FY 2026 delivered record annual sales revenue of AUD 23.9 million, up 30% year-over-year from AUD 18.4 million in FY 2025, with Q4 marking strategic milestones for future growth.

• Biome Daily became the top probiotic product in Australian pharmacies by units and dollar value, establishing a strong platform for expansion.

• June 2026 marked the first month with consumer sell-through of Activated Probiotics exceeding 100,000 units.

• Strategic wins included a binding onshore manufacturing agreement and the advancement of proprietary probiotic strain BMB18, with international clinical trials and a patent application lodged.

Financial highlights

• FY 2026 revenue was AUD 23.9 million, a 30% increase from FY 2025's AUD 18.4 million.

• Q4 cash receipts from customers were AUD 5.9 million, up AUD 1.1 million sequentially and 61% year-over-year.

• Net operating cash inflow for Q4 was AUD 708K, a turnaround of nearly AUD 2 million from Q3.

• Cash balance at 30 June was AUD 3.6 million, with debt reduced to AUD 1.9 million and AUD 3.1 million undrawn facility headroom.

• Full-year net operating cash inflow was AUD 1.6 million, compared to a cash outflow of AUD 1.4 million in FY 2025.

Outlook and guidance

• FY 2027 is expected to be the highest revenue-generating half in company history, supported by new product launches and international expansion.

• Vision 2027 target reaffirmed at AUD 32 million+ in revenue for the financial year, with accelerated growth anticipated.

• Onshore manufacturing to commence in Q1 FY27, expected to improve cost structure and working capital efficiency.

• New digital health initiatives, including a B2B2C e-commerce platform, will be piloted in the U.K.